Table 3.
Shift in best tumor response using WHO criteria and mRECIST in cohorts A and B
|
Cohort A | ||||||||||
| mRECIST best response |
WHO best responsea |
|||||||||
| CR | PR | SD | PD | UTD | Total | |||||
| CR | 1 | 1 | 3 | 0 | 0 | 5 | ||||
| PR | 0 | 1 | 6 | 2 | 0 | 9 | ||||
| SD | 0 | 1 | 14 | 14 | 0 | 29 | ||||
| PD | 0 | 0 | 1 | 4 | 0 | 5 | ||||
| UTD | 0 | 0 | 0 | 0 | 7 | 7 | ||||
| Total | 1 | 3 | 24 | 20 | 7 | 55 | ||||
|
Cohort B | ||||||||||
| mRECIST best response |
WHO best responsea |
|||||||||
| CR | PR | SD | PD | UTD | Total | |||||
| CR | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| PR | 0 | 2 | 2 | 1 | 0 | 5 | ||||
| SD | 0 | 0 | 14 | 14 | 0 | 28 | ||||
| PD | 0 | 0 | 2 | 5 | 0 | 7 | ||||
| UTD | 0 | 0 | 0 | 0 | 6 | 6 | ||||
| Total | 0 | 2 | 18 | 20 | 6 | 46 | ||||
Cohort A: brivanib alaninate 800 mg once daily and no prior systemic therapy; cohort B: brivanib alaninate 800 mg once daily and prior systemic therapy.
a
Independent Response Review Committee assessment. UTD=unable to determine.